Immunology Investor Event

Dupixent: Atopic Dermatitis Adult 18+ Number of patients (thousands) Prevalence Treated 5,722 8,174 7,136 5,231 1,038 11,991 Moderate-to-Severe 2,638 2,997 595 6,230 Biologics eligible 1,675 1,121 222 3,018 Most in need 301 189 100 590 0 2,000 4,000 6,000 US 1,416 16,726 Moderate-to-Severe uncontrolled sanofi 8,000 10,000 12,000 14,000 16,000 18,000 Europe(1) Japan Treated with multiple systemic steroids or one immunosuppressant or phototherapy(2) Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom. (2) For EU, patients who have inadequate response or intolerant to immunosuppressants 2 Immunology Investor Event

View entire presentation